Ollin Biosciences Raises $330M to Advance Late-Stage Eye Disease Drug

Austin, Texas-based Ollin Biosciences has closed an oversubscribed $330 million Series B funding round co-led by Palo Alto, Calif.-based TCGX... Read More

The post Ollin Biosciences Raises $330M to Advance Late-Stage Eye Disease Drug appeared first on citybiz.